Sang-Hoon Ahn1, Young-Oh Kweon2, Seung-Woon Paik3, Joo-Hyun Sohn4, Kwan-Sik Lee5, Dong Joon Kim6, Teerha Piratvisuth7, Man Fung Yuen8, Anuchit Chutaputti9, You-Chen Chao10, Aldo Trylesinski11, Claudio Avila12. 1. Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seoul, South Korea. ahnsh@yuhs.ac. 2. The Kyungpook National University Hospital, Daegu, Korea. yokweon@knu.ac.kr. 3. Department of Medicine/Gastroenterology, Samsung Medical Centre, Seoul, Korea. sw.paik@samsung.com. 4. Division of Gastroenterology, Hanyang University Guri Hospital, Gyeonggi-do, Suwon, Korea. sonjh@hanyang.ac.kr. 5. Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. leeks519@yuhs.ac. 6. Hallym University Sacred Heart Hospital, Chuncheon, Korea. djkim@hallym.ac.kr. 7. NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand. teerha.p@psu.ac.th. 8. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong. mfyuen@hkucc.hku.hk. 9. Phramongkutklao Hospital, Bangkok, Thailand. anuchitwcog2002@hotmail.com. 10. Tri-Service General Hospital, Taipei, Taiwan, R.O.C. chaoycmd@yahoo.com.tw. 11. Novartis Pharma AG, Basel, Switzerland. aldo.trylesinski@novartis.com. 12. Novartis Pharma AG, Basel, Switzerland. claudio.avila@novartis.com.
Abstract
PURPOSE:Lamivudine (LAM) resistance is common on lamivudine monotherapy for chronic hepatitis B. This study examined the safety and efficacy of telbivudine (LDT) given with adefovir (ADV) versus ADV monotherapy in patients with chronic, lamivudine-resistant HBV infection. METHODS: An open-label, 96 week study with planned recruitment of 150 HBeAg-positive, lamivudine-experienced Asian patients with a confirmed YMDD resistance mutation, randomized 1:1 to receive ADV alone or with LDT. The study was terminated early due to difficulty in enrolling monotherapy patients. At termination, 42 patients had received study medication for 8-61 weeks. Due to incomplete enrolment, summary statistics only were prepared, without significance testing. RESULTS: A total of 42 patients underwentrescue therapy (switch to ADV or LDT + ADV; n = 21 per group). Median treatment duration was 48 weeks in both groups. HBV DNA changes from baseline were greater in the LDT + ADV arm at all time points (Week 48: -7.4 log10 vs. -4.9 log10 copies/ml), and serum DNA was undetectable (<300 copies/mL) at week 48 in 38.5% (5/13) on LDT + ADV versus 0% (0/9) on ADV monotherapy Two patients (9.6%) on ADV monotherapy experienced virologic breakthrough without evidence of ADV resistance, but none on LDT + ADV; and no confirmed ADV resistance was observed in any on-treatment sample. HBeAg loss occurred in three patients on LDT + ADV and one patient on ADV monotherapy through week 48. Safety profiles were similar between the arms. CONCLUSION:LDT + ADV combination treatment showed better outcomes against lamivudine resistant HBV than ADV alone, with a similar safety profile.
RCT Entities:
PURPOSE:Lamivudine (LAM) resistance is common on lamivudine monotherapy for chronic hepatitis B. This study examined the safety and efficacy of telbivudine (LDT) given with adefovir (ADV) versus ADV monotherapy in patients with chronic, lamivudine-resistant HBV infection. METHODS: An open-label, 96 week study with planned recruitment of 150 HBeAg-positive, lamivudine-experienced Asian patients with a confirmed YMDD resistance mutation, randomized 1:1 to receive ADV alone or with LDT. The study was terminated early due to difficulty in enrolling monotherapy patients. At termination, 42 patients had received study medication for 8-61 weeks. Due to incomplete enrolment, summary statistics only were prepared, without significance testing. RESULTS: A total of 42 patients underwent rescue therapy (switch to ADV or LDT + ADV; n = 21 per group). Median treatment duration was 48 weeks in both groups. HBV DNA changes from baseline were greater in the LDT + ADV arm at all time points (Week 48: -7.4 log10 vs. -4.9 log10 copies/ml), and serum DNA was undetectable (<300 copies/mL) at week 48 in 38.5% (5/13) on LDT + ADV versus 0% (0/9) on ADV monotherapy Two patients (9.6%) on ADV monotherapy experienced virologic breakthrough without evidence of ADV resistance, but none on LDT + ADV; and no confirmed ADV resistance was observed in any on-treatment sample. HBeAg loss occurred in three patients on LDT + ADV and one patient on ADV monotherapy through week 48. Safety profiles were similar between the arms. CONCLUSION:LDT + ADV combination treatment showed better outcomes against lamivudine resistant HBV than ADV alone, with a similar safety profile.
Authors: Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Wangdon Yoo; Soo-Ok Kim Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: M I Allen; M Deslauriers; C W Andrews; G A Tipples; K A Walters; D L Tyrrell; N Brown; L D Condreay Journal: Hepatology Date: 1998-06 Impact factor: 17.425
Authors: M Buti; I Elefsiniotis; R Jardi; V Vargas; F Rodriguez-Frias; M Schapper; S Bonovas; R Esteban Journal: J Hepatol Date: 2007-05-24 Impact factor: 25.083
Authors: Man-Fung Yuen; Wai-Kay Seto; Danny Hoi-Fan Chow; Kit Tsui; Danny Ka-Ho Wong; Vincent Wing-Shun Ngai; Benjamin Chun-Yu Wong; James Fung; John Chi-Hang Yuen; Ching-Lung Lai Journal: Antivir Ther Date: 2007
Authors: Marion G Peters; H w Hann Hw; Paul Martin; E Jenny Heathcote; P Buggisch; R Rubin; M Bourliere; K Kowdley; C Trepo; D f Gray Df; M Sullivan; K Kleber; R Ebrahimi; S Xiong; Carol L Brosgart Journal: Gastroenterology Date: 2004-01 Impact factor: 22.682
Authors: Eugene R Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S Choy; Sally Van Doren; John Fry; Carol L Brosgart Journal: Hepatology Date: 2003-12 Impact factor: 17.425
Authors: Hana Park; Jun Yong Park; Seung Up Kim; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn Journal: World J Gastroenterol Date: 2013 Impact factor: 5.742
Authors: Sangheun Lee; Jun Yong Park; Kijun Song; Do Young Kim; Beom Kyung Kim; Seung Up Kim; Hye Jin Ku; Kwang-Hyub Han; Sang Hoon Ahn Journal: Gut Liver Date: 2015-11-23 Impact factor: 4.519